1.
Arch Mal Coeur Vaiss
; 96(6): 683-5, 2003 Jun.
Artigo
em Francês
| MEDLINE
| ID: mdl-12868352
RESUMO
Type 2 cyclo-oxygenase inhibitors are new anti-inflammatory drugs with better gastrointestinal tolerance than traditional non-steroidal anti-inflammatory drugs. They have no platelet anti-aggregant effects and there is still some discussion as to whether this new therapeutic class has any pro-thrombotic effects. The authors report two cases of myocardial infarction in patients considered to be at low risk treated by type 2 cyclo-oxygenase inhibitors.